Bioventix PLC (AIM:BVXP)

Market Cap	102.93M -8.4%
Revenue (ttm)	12.97M -1.1%
Net Income	7.61M +0.4%
EPS	1.44 +0.2%
Shares Out	5.22M
PE Ratio	13.72
Forward PE	13.76
Dividend	1.50 (7.61%)
Ex-Dividend Date	Nov 5, 2026

Volume	5,785
Open	1,982.50
Previous Close	1,970.00
Day's Range	1,955.00 - 2,000.00
52-Week Range	1,300.00 - 2,227.55
Beta	0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 12
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In fiscal year 2026, Bioventix's revenue was 12.97 million, a decrease of -1.10% compared to the previous year's 13.12 million. Earnings were 7.61 million, an increase of 0.40%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error